Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation

Hans F A Vasen, Martin Wasser, Anneke Van Mil, Rob A. Tollenaar, Marja Konstantinovski, Nelleke A. Gruis, Wilma Bergman, Frederik J. Hes, Daniel W. Hommes, G. Johan A Offerhaus, Hans Morreau, Bert A. Bonsing, Wouter H. De Vos Tot Nederveen Cappel

Research output: Contribution to journalArticle

Abstract

Background & Aims: Surveillance of high-risk groups for pancreatic cancer might increase early detection and treatment outcomes. Individuals with germline mutations in p16-Leiden have a lifetime risk of 15% to 20% of developing pancreatic cancer. We assessed the feasibility of detecting pancreatic cancer at an early stage and investigated the outcomes of patients with neoplastic lesions. Methods: Individuals with germline mutations in p16-Leiden (N = 79; 31 male; mean age, 56 years; range, 3972 years) were offered annual surveillance by magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP). Those found to have neoplastic lesions were offered options for surgery or intensive follow-up. Individuals found to have possible neoplastic lesions were examined again by MRI/MRCP within 2 to 4 months. Results: After a median follow-up period of 4 years (range, 010 years), pancreatic cancer was diagnosed in 7 patients (9%). The mean age at diagnosis was 59 years (range, 4972 years). Three of the tumors were present at the first examination, and 4 were detected after a negative result in the initial examination. All 7 patients had a resectable lesion; 5 underwent surgery, 3 had an R0 resection, and 2 had lymph node metastases. Possible precursor lesions (ie, duct ectasias, based on MRCP) were found in 9 individuals (11%). Conclusions: MRI/MRCP detects small, solid pancreatic tumors and small duct ectasias. Although surveillance increases the rate of resectability, carriers of a p16-Leiden mutation develop agressive tumors.

Original languageEnglish (US)
Pages (from-to)850-856
Number of pages7
JournalGastroenterology
Volume140
Issue number3
DOIs
StatePublished - Mar 2011
Externally publishedYes

Keywords

  • Cancer Prevention
  • Cancer Screening
  • Imaging Studies
  • Tumor Suppressor

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation'. Together they form a unique fingerprint.

  • Cite this

    Vasen, H. F. A., Wasser, M., Van Mil, A., Tollenaar, R. A., Konstantinovski, M., Gruis, N. A., Bergman, W., Hes, F. J., Hommes, D. W., Offerhaus, G. J. A., Morreau, H., Bonsing, B. A., & De Vos Tot Nederveen Cappel, W. H. (2011). Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology, 140(3), 850-856. https://doi.org/10.1053/j.gastro.2010.11.048